Prescription THC drug cuts PTSD nightmares in 10-week trial

A controlled clinical trial found that a prescription medicine containing tetrahydrocannabinol (THC) eased trauma-related nightmares in people diagnosed with post-traumatic stress disorder (PTSD). The results were collected over a ten-week treatment period, with outcomes assessed in a structured research setting.

Researchers tested Dronabinol, which they described as a synthetic form of THC. The study used a double-blind, placebo-controlled design, meaning neither participants nor investigators knew who received Dronabinol versus placebo during the trial.

Nightmare burden fell more with Dronabinol than placebo Nightmare burden fell more with Dronabinol than placebo The main reported improvement involved trauma nightmares measured The main reported improvement involved trauma nightmares measured on a standardized tool. Researchers said Dronabinol led to a larger reduction in nightmare burden than placebo over the ten weeks. Participants who received Dronabinol recorded a 3.7-point reduction in nightmare burden. Those given placebo showed a 2.2-point reduction on the same measure, according to the trial results. The study also reported patient-reported changes that went beyond average score shifts. More than one-third of participants said their trauma nightmares stopped entirely during the treatment period, and more than half reported a measurable decrease in symptom severity.

Effects were limited to sleep-related trauma symptoms

Researchers emphasized that the findings did not translate Researchers emphasized that the findings did not translate into clear improvements across PTSD more generally. They said the trial did not provide conclusive evidence that Dronabinol reduced overall PTSD severity. The team also reported no conclusive evidence of improvement in comorbid depression. As presented by the authors, the benefits observed in this study were concentrated on nightmare burden and related sleep symptoms rather than a broad change across PTSD-associated outcomes. Side effects were mild to moderate; no withdrawal signals reported Adverse effects were described as mild to moderate. Reported side effects included dizziness, headaches, and increased appetite. According to the study, researchers observed no signs of dependence or withdrawal when the medication was stopped. They highlighted this alongside the overall tolerability profile described during the ten-week trial.

Why the results are drawing interest

Researchers said the findings may matter because standard Researchers said the findings may matter because standard PTSD treatments often provide limited relief for nocturnal symptoms, including trauma-related nightmares. On that basis, they said the data suggest a possible role for a prescription cannabinoid option aimed at a defined sleep-related aspect of PTSD.

The authors added that the results could help inform future regulatory discussions about cannabinoids for specific psychiatric uses. At the same time, they underscored uncertainty around broader PTSD and depression outcomes in this study, framing the evidence as strongest for nightmare-focused relief rather than comprehensive symptom improvement.